Axogen, Inc. filed an amendment to its Form 8-K to include the Agreement and Plan of Merger with BioCircuit Technologies, Inc., and a corrected investor presentation. The company agreed to acquire BioCircuit for $200 million in cash, subject to customary adjustments. The transaction is expected to close in Q4 2026 and will be funded substantially through net proceeds from an equity offering. BioCircuit commercializes NerveTape, the first FDA-cleared device for sutureless nerve repair, which generated approximately $11 million in revenue in 2025 and runs at a ~$24 million annualized rate as of Q2 2026. Axogen anticipates the acquisition to be accretive to revenue growth and adjusted EBITDA margins in Year 1 while maintaining free cash flow positivity. Axogen, Inc. operates in the medical device industry, specializing in peripheral nerve repair technologies.

On September 9, 2026, Axogen, Inc. entered into a definitive merger agreement to acquire BioCircuit Technologies for $200 million in cash, subject to customary adjustments. The transaction is expected to close in the fourth quarter of 2026 and will add NerveTape, the first FDA-approved device for sutureless peripheral nerve repair, to Axogen's portfolio. To finance the acquisition, Axogen priced a public offering of 4,910,000 shares at $42.50 per share on September 10, 2026, generating approximately $208.7 million in gross proceeds before underwriting discounts. The company intends to use substantially all net proceeds from the equity offering for the cash consideration and related fees. Axogen operates in the medical device industry, developing and commercializing surgical solutions for peripheral nerve regeneration and repair.

Axogen, Inc. reported second quarter 2026 financial results with revenue of $69.7 million, representing a 23.1% increase from the prior year period. The company raised its full-year 2026 revenue guidance to at least $279 million, reflecting expected growth of at least 24%. Axogen reported a GAAP net loss of $1.5 million, or $0.03 per share, compared to net income of $0.6 million in the same quarter last year. Adjusted net income was $7.3 million, or $0.12 per share, while adjusted EBITDA came in at $8.4 million. The company holds $113.4 million in cash and investments as of June 30, 2026, having extinguished its long-term debt during the first half of the year. Axogen operates in the medical device industry, developing and marketing innovative surgical solutions for peripheral nerve regeneration and repair.